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Abstract
Background: Different isoforms of VEGF-A (mainly VEGF121, VEGF165 and VEGF189) have been shown to display
particular angiogenic properties in the generation of a functional tumor vasculature. Recently, a novel class of
VEGF-A isoforms, designated as VEGFxxxb, generated through alternative splicing, have been described. Previous
studies have suggested that these isoforms may inhibit angiogenesis. In the present work we have produced
recombinant VEGF121/165b proteins in the yeast Pichia pastoris and constructed vectors to overexpress these
isoforms and assess their angiogenic potential.
Results: Recombinant VEGF121/165b proteins generated either in yeasts or mammalian cells activated VEGFR2 and
its downstream effector ERK1/2, although to a lesser extent than VEGF165. Furthermore, treatment of endothelial
cells with VEGF121/165b increased cell proliferation compared to untreated cells, although such stimulation was
lower than that induced by VEGF165. Moreover, in vivo angiogenesis assays confirmed angiogenesis stimulation by
VEGF121/165b isoforms. A549 and PC-3 cells overexpressing VEGF121b or VEGF165b (or carrying the PCDNA3.1 empty
vector, as control) and xenotransplanted into nude mice showed increased tumor volume and angiogenesis
compared to controls. To assess whether the VEGFxxxb isoforms are differentially expressed in tumors compared to
healthy tissues, immunohistochemical analysis was conducted on a breast cancer tissue microarray. A significant
increase (p < 0.05) in both VEGFxxxb and total VEGF-A protein expression in infiltrating ductal carcinomas
compared to normal breasts was observed. A positive significant correlation (r = 0.404, p = 0.033) between
VEGFxxxb and total VEGF-A was found.
Conclusions: Our results demonstrate that VEGF121/165b are not anti-angiogenic, but weakly angiogenic isoforms of
VEGF-A. In addition, VEGFxxxb isoforms are up-regulated in breast cancer in comparison with non malignant breast
tissues. These results are to be taken into account when considering a possible use of VEGF121/165b-based therapies
in patients.
Background
Angiogenesis is a process by which new blood vessels
are formed from pre-existing ones [1]. In physiological
conditions, this process is strictly controlled by a set of
molecules that can either activate the process (proangio-
genic factors) or inhibit it (antiangiogenic factors) [2].
During the last decades, it has been widely established
that solid tumors have abnormal hyperactivation of
angiogenesis [2]. Among the factors that can trigger
angiogenesis, the lack of oxygen (hypoxia) is of special
importance. Virtually all solid tumors eventually activate
angiogenesis in order to overcome lack of oxygen and
nutrients after reaching a certain burden [3,4]. One of
the most important mediators of hypoxia-activated
angiogenesis is the Vascular Endothelial Growth Factor
(VEGF-A), produced by tumor cells after sensing low
oxygen levels [5,6]. VEGF-A expression can also be
induced by non-hypoxia mediated activation, such as
Ras signalling [7].
VEGF-A is a key player in tumor-induced angiogen-
esis, and its overexpression has been found in most
solid tumor types [6]. VEGF-A acts through its cognate
receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR), in
* Correspondence: acalvo@unav.es
1Laboratory of Novel Therapeutic Targets. Division of Oncology, Center for
Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain
Full list of author information is available at the end of the article
Catena et al. Molecular Cancer 2010, 9:320
http://www.molecular-cancer.com/content/9/1/320
© 2010 Catena et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.endothelial and bone marrow-derived cells [6,8]. The
VEGF pathway has been used as a major target to block
tumor angiogenesis. A set of molecules that bind and
inhibit different components of the VEGF-A pathway
have been developed during the past years. Some of
them have already reached the clinical practice, such as
bevacizumab (Avastin®, Genentech), a monoclonal anti-
body that binds and inactivates VEGF-A, or sunitinib
(Sutent®, Pfizer), a tyrosine-kinase inhibitor that blocks
phosphorylation of several tyrosine-kinase receptors
including VEGFR1 and VEGFR2 [9,10].
The VEGF-A gene contains 8 exons, which can give
rise to 5 main alternatively spliced isoforms (VEGF121,
VEGF145,V E G F 165,V E G F 189 and VEGF206) [6]. Alterna-
tive translation codons upstream of the canonical ATG
codon can be used, so that longer isoforms can also be
generated [11]. However, ther e l a t i v ei m p o r t a n c eo f
these members is still undetermined. Recently, a novel
set of isoforms, the so-called “b-isoforms” or “VEGFxxxb”
isoforms, have been described. These transcripts of the
VEGF-A gene code for polypeptides with the same
length as the classical ones, because exon 8 (present in
all the formerly known isoforms) is substituted by an
alternatively spliced exon of the same size (exon 8b)
[12]. These isoforms were therefore named VEGF121b,
VEGF165b, VEGF189b etc. In the classically studied iso-
forms, exon 8 is known to be important for receptor
activation [13]. Thus, the “b-isoforms”,w h e r ee x o n8i s
substituted by another peptide sequence, were
hypothesized to act as potential antagonists of VEGF-A
receptors [14]. Several reports have indeed shown that
VEGF165b may have anti-angiogenic properties [14,15],
while others cast some doubts about such activities, sug-
gesting that it may act as a VEGF-A receptor agonist
[16,17].
Another interesting issue is the possible differential
expression between “angiogenic” vs. “antiangiogenic”
isoforms in pathologies where development of aberrant
vasculature is involved, including cancer. Previous stu-
dies have shown in a limited number of samples, using
semiquantitative RT-PCR, that VEGFxxxbi s o f o r m sa r e
highly expressed in normal prostate, colon and kidney
compared to their malignant counterparts [14,18,19]. It
was proposed that formation of neovasculature in patholo-
gical conditions would modify alternative splicing of VEGF-
A, thus promoting the expression of the “b-isoforms”
(supposedly anti-angiogenic) at the expense of the classical
angiogenic family of isoforms. This would also be extremely
interesting because expression of the ratio VEGFxxxb/
VEGF could be utilized as a biomarker of angiogenic
disease [13].
Since a therapeutic approach using recombinant
VEGFxxxb proteins is very attractive, but the biological
activity of such transcripts is not yet clear, we sought to
produce recombinant VEGF121ba n dV E G F 165bp r o t e i n s
in the yeast Pichia pastoris, and constructed expression
vectors to overexpress these isoforms, in order to
further elucidate their role in cancer models. In addi-
tion, we analyzed protein expression of VEGFxxxba n d
total VEGF in normal mammary glands and 50 breast
cancer samples, using specific antibodies previously
characterized.
Methods
Cloning of VEGF121b and VEGF165b
Oligonucleotides were purchased to Sigma-GenoSys
(Sigma, St. Louis, MO, USA). The primers VF (5’GAAAC-
CATGAACTTTCTGCTGTCTT3’) and V121bR (5’
TTAAGCTTTCAGTCTTTCCTGGTGAGAGATTTTT-
CTTGTCTTGCTCTATC3’)w e r eu s e dt oc l o n et h e
VEGF121bi s o f o r mb yP C Ri n t op C R 2 . 1v e c t o r( I n v i t r o -
gen). VF and V165bR (5’ TTAAGCTTTCAGTC-TTT
CCTGGTGAGAGATCTGCAAGTACGTTCGTTTAAC
TC 3’)w e r eu s e dt oc l o n eV E G F 165b. Note that initia-
tion codon is underlined in VF and both reverse oligo-
nucleotides contain HindIII restriction sites (bold).
VEGF121ba n dV E G F 165b coding sequences were then
subcloned into the pCDNA3.1(-)Neo expression plas-
mid. The primer VPPF (5’ GGTCTCGAGAAAAGA-
GAGGCTGAAGCTGCACCCATGGCAGAAGG 3’),
together with V121bR or V165bR, was used to clone
VEGF121ba n dV E G F 165b coding sequences lacking the
signal peptide (ΔPSVEGFxxxb) into the pPICZalphaC
vector (Invitrogen) for production of recombinant pro-
teins in the yeast Pichia pastoris, where the alpha-fac-
tor signal peptide is used to achieve extracellular
expression of the VEGFxxxb sequences.
Recombinant protein production and purification
The pPICZalphaC plasmids carrying the ΔPS-VEGFxxxb
sequences were linearized, gel-purified, and measured
for concentration. 80 μLo fPichia pastoris cells were
mixed with 5 μg of linearized-plasmid in 1 mm-wide
electroporation cuvettes (Bio-Rad). Electroporation was
carried out in a Gene-pulser II (Bio-Rad) using the pre-
set yeast conditions. After electroporation, 1 mL of 1 M
sorbitol was added to the cuvettes and the electropo-
rated cells were transferred to sterile microtubes. Yeasts
w e r ei n c u b a t e da t3 0 ° Cf o r2ha n dt h e ns p r e a di n
YPDSZ plates (1% yeast extract, 2% peptone, 2% sorbi-
tol, 2% agar and 100 μg/mL zeocin) and incubated for
9 days at 29°C. Zeocin-resistant colonies were picked
and grown in YPD medium. Yeast clones were trans-
ferred to BMGY medium (1% yeast extract, 2% peptone,
100 mM potassium phosphate pH 6.0, 1.34% yeast nitro-
gen base, 0.00004% Biotin, 1 U/mL gentamycin sulphate,
and 1% glycerol) to allow cells to grow exponentially for
30 h at 29°C and thorough shaking. Yeasts were then
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same composition as BMGY but containing 1% metha-
nol instead of glycerol) to induce protein production.
Supernatants were collected 24 hours after incubation at
29°C and thorough shaking, and analyzed by SDS-PAGE
to determine the best clone producing each of the
VEGF121/165b isoforms. Selected clones were grown at
29°C in 2 L of BMGY for 2 days and then changed to
BMMY inducing medium, in order to produce large
amounts of recombinant products. For purification,
nickel-affinity chromatography was used. A Hi-Trap che-
lating column (Amersham) was connected to an AKTÄ
High Pressure Liquid Chromatography (HPLC) device
(Amersham). Pichia pastoris supernatants containing
recombinant VEGF121/165b proteins were diluted in bind-
ing buffer (0.02 M sodium phosphate, 1 M NaCl, pH 7.2;
all reagents from Sigma) and loaded into the HPLC
device. Elution buffer (0.02 M sodium phosphate, 1 M
NH4Cl, 500 mM Imidazole, pH 7.2; all reagents from
Sigma, except for imidazole, purchased from Merck) was
loaded, and gradually mixed with binding buffer with an
increasing proportion of elution buffer. Fractions of 1 mL
were collected throughout the process.
Purified proteins after affinity chromatography were
depleted from eluting medium and changed to PBS through
dialysis, using Slide-A-lyzer cassettes (Pierce) with a 10 KDa
threshold pore. Cassettes were filled with eluted protein
and drawn in 3L of PBS, overnight. This step was repeated
with new PBS for 6 more hours. Dialyzed proteins were
extracted from the cassettes with syringes and snap frozen.
Protein extraction, electrophoresis and western blot
For protein extraction, cultured cells were lysed for
30 min at 4°C in RIPA buffer (50 mM Tris pH 7.4,
1 5 0m MN a C l ,1m MP M S F ,1m ME D T A ,1 %s o d i u m
deoxycholate and 0.1% sodium dodecyl sulphate; all
reagents from Sigma) plus a protease inhibitor cocktail
(Roche, Switzerland). Samples were then centrifuged at
13000 rpm. Protein concentration was determined by the
bicinchoninic acid protein assay (Pierce, Rockford, IL). In
the case of conditioned culture media, supernatants were
centrifuged to get rid of any cell debris and 20-fold con-
centrated by centrifugation for 45 min, using 15-KDa
Amicon Ultra centricons (Millipore, Billerica, MA, USA).
Proteins were electrophoresed in Bis-Tris buffered gels
(Novex gels, Invitrogen) in either reducing or non-redu-
cing conditions, following standard procedures. 20 μg
p r o t e i ns o l u t i o n( i nR I P Ab u f f e r )w e r em i x e dw i t h
Laemmli sample buffer and boiled for 5 min. Electro-
phoresis was carried out in 1X running buffer for
90 min at 130V and room temperature. Proteins were
directly stained in the gel with Coomassie blue or trans-
ferred to PVDF membranes for immunodetection.
Deglycosylation analysis of VEGFxxxbp r o t e i n s( 9 0μM)
was treated with 0.8 mM Endo F1 and incubated for 1 h
at 37°C; cleavage was monitored by SDS-PAGE.
Membranes for western blots were rinsed twice with
PBS-tween, blocked with PBST plus 5% skim milk for 30
min at room temperature, and incubated with primary
antibodies. Antibodies against VEGF (MAB293, R&D;
and sc-152, Santa Cruz), VEGFxxxb (MAB3045, R&D),
pKDR, total KDR, pERK1/2, total ERK1/2, and GAPDH
(all of these latter ones from Cell Signalling) were used.
Then, horseradish peroxidase-labelled secondary antibo-
dies (GE Healthcare) against the corresponding primary
antibodies were added. Immunoreactive bands were
visualized by a chemoluminescent method using the
Lumi-lightPLUS kit (Roche).
Cell Culture
HUVECs, PC3 and A549 cell lines were obtained from
the American Type Culture Collection (ATCC, Mana-
ssas, VA, USA). PC3 and A549 cells were maintained in
complete medium, consisting of: RPMI-1640 growth
medium (Invitrogen) with Glutamax®, supplemented
with 10% heat-inactivated FBS, 100 U/mL penicillin and
100 μg/mL streptomycin (both antibiotics from Invitro-
gen). HUVECs were maintained in EGM-MV2 medium
(Lonza) containing human recombinant EGF, VEGF,
FGF, IGF-1, hydrocortisone, ascorbic acid and 2% FBS.
Cell culture medium with 1% serum was used to analyze
cells supernatants by western blot.
Purified plasmidic DNA was introduced into mamma-
lian cells through cationic lipid-based transfection with
the reagent Lipofectamine 2000, according to manufac-
turer’s recommendations. Transfected cells were selected
and maintained with complete medium plus 300 μg/mL
(PC3) or 500 μg/mL (A549) G418.
Cell proliferation assays
Two different methods were used to assess cell prolif-
eration. The first method consisted of the MTT (Sigma-
Aldrich, Italy) assay. Cells were seeded in 50 μL2 %
FBS-containing growth medium in 96-well culture plates
and allowed to attach overnight. Two-fold concentrated
recombinant human VEGF165 (rhVEGF165, Apollo Cyto-
kine Research), recombinant human VEGF121ba n d
VEGF165b produced in Pichia pastoris (VEGF121b(pp)
and VEGF165b(pp)), recombinant human VEGF165bp r o -
duced in CHO cells (VEGF165b(hs)), kindly provided by
Dr. David O. Bates (Microvascular Research Labora-
tories, Department of Physiology, University of Bristol,
UK), or the VEGFRs inhibitor GW654652 (Glaxo-
SmithKline) were added. In each time point, 10 μL5 %
MTT solution was added to each well. Plates were incu-
bated for additional 3 h at 37°C. The resulting formazan
crystals were finally solubilized by administration of
100 μl 10% SDS in 50% N-N-Dimethylformamide to
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sured using a TECAN Sunrise microplate reader. Wells
containing only complete medium were used as con-
trols. Each experiment was performed three times using
six replicates for each drug concentration.
The second method consisted of analysis of DNA
synthesis by incorporation of the modified nucleotide
EdU, using the Click-it reaction according to the manu-
facture’s instructions (Invitrogen). Briefly, cells were pla-
ted at 50% confluence and treated with 50 or 100 ng/
mL of rhVEGF165,V E G F 121b(pp), VEGF165b(pp), or
bFGF overnight. Cells were then incubated for 1 h with
5 mM EdU solution, washed, trypsinized, fixed, permea-
bilized, and incubated with Alexa-Fluor-647 dye in the
presence of copper for catalysis of the Click-it reaction.
Cells were analyzed with a FACScalibur flow cytometer
to determine EdU incorporation.
Tumor xenograft and Matrigel plug assays
Nu/Nu mutant athymic mice (Balb/C genetic back-
ground) were purchased from Harlan Laboratories
(Barcelona, Spain) and maintained in SPF (Specific
Pathogen Free) standard conditions. One million PC3 or
five million A549 cells and their corresponding transfec-
tants in exponential growth phase were resuspended in
200 μL PBS and injected subcutaneously in the flanks of
Nu/Nu mice. Tumor measurements were done with pre-
cision callipers and animals were sacrificed before
tumors reached 1.7 cm in diameter. Experiments were
conducted according to the guidelines for ethical use of
animals of our Institution (CIMA-University of Navarra)
under an approved protocol. Tumors were harvested
and fixed overnight in 10% buffered formalin, embedded
in paraffin, and sectioned. Primary tumor volumes were
calculated with the formula: V = length × (width)
2/2.
For Matrigel plug assays, 400 μL Growth Factor
Reduced Matrigel (BD) were mixed with 100 ng of
rhVEGF165,V E G F 121b(pp), VEGF165b(pp), or bFGF (as
positive control) in 100 μL PBS and injected subcuta-
neously in Nu/Nu mice. One week after cell inoculation,
mice were injected retro-orbitally with 100 mL Fluores-
cein-labelled dextran (3 mg/mL) or with Alexa-647-
labelled isolectin B4 (100 μg/mL). After 15 min, mice were
sacrifized, and the Matrigel plugs were explanted and ana-
lyzed under a Zeiss Axiovert confocal microscope.
Immunohistochemistry, fluorescence analysis and
quantification
Tissues (xenografted tumors or matrigel plugs) were
obtained from the in vivo experiments, fixed in 10% buf-
fered formalin and embedded in paraffin. Tissue Micro-
array (TMA) slides were obtained from AccuMax
(Seoul, Korea; catalogue # A202(I)). This TMA contains
100 breast tissue cores from 50 patients and 8 tissue
cores from 4 normal breast tissue obtained by mammo-
plasty. Breast cancer types include 33 infiltrating ductal
carcinomas, 7 papillary carcinomas, 3 phyllodes tumors,
4 infiltrating lobular carcinomas, and 3 samples corre-
sponding to other breast cancer tumor types.
For immunohistochemistry, slides were deparaffinized,
hydrated, and incubated for 10 min with 3% H2O2 in
water to quench the endogenous peroxidase activity. An
antigen retrieval method was used for detection of the
antibodies. Dilutions of primary antibodies were as fol-
lows: 1:200 for Caspase 3 (Cleaved Caspase-3 Asp 175,
Cell Signaling); 1:20 for CD-31 (Dianova); 1:100 for
PDGFRb (Cell Signaling); 1:200 for VEGF (Santa Cruz);
1:50 for VEGFxxxb (R&D). Primary antibodies were incu-
bated at 4°C overnight or for 1 h at RT in the case of
CD31. Tissues were washed in TBS and incubated with
the appropriate secondary antibody. Afterwards, slides
were incubated for 30 min with the EnVision™ anti-
rabbit detection system (Dako). Peroxidase activity was
carried out with DAB (Dako). Finally, slides were coun-
terstained with hematoxylin, dehydrated, and mounted.
For quantifications of immunohistochemistry in xeno-
grafted tumor sections, 10 random images (200×) per
mouse were captured with a microscope (Leica, Wetzlar,
Germany) equipped with the Analysis™ software. Positive
cells were quantified with Image J (NIH, Bethesda, MD,
USA). Measurements are given as relative area occupied
by the stained tissue with respect to the reference area
(for CD-31 and PDGFRb) or percentage of positive cells
(for active caspase-3). For the TMA, a semiquantifica-
tion procedure was performed according to a score that
takes into account the extension and intensity of the
immunoreactivity signal. The “0” score was assigned
when the sample was completely negative. Score “1”
meant weak signal; Score “2”, strong and widespread sig-
nal; and Score “3”, very strong and widespread signal.
Signal was considered positive when at least 10% of the
cells were positive.
For quantification of FITC-dextran and Alexa-647 Isolec-
tin B4 in sections of Matrigel plugs, slides were analyzed
with an Axiovert (Carl Zeiss, Germany) epifluorescence
microscope and 10 random pictures of each Matrigel were
taken. Labelled area was measured with the ImageJ
software.
Statistical analysis of data
Data sets were tested for normal distribution with
Shapiro-Wilks and Kolgomorov-Smirnoff tests. Levene’s
test was also performed to verify homogeneity of var-
iances. In those cases where tests displayed normal dis-
tribution, ANOVA was performed to test for possible
differences among groups. Bonferroni correction was
used for post-hoc comparison in the case of variance
homogeneity, whereas Tamhane’s correction was the
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mal distributed data sets, non-parametric tests were
applied: Kruskal-Wallis for multiple comparisons and
Mann-Whitney’s U-test with significance correction for
double comparisons of independent samples. Wilcoxon’s
test was carried out for dependent sample data. To run
these tests, The SPSS software was used. Results with a p-
value < 0.05 were considered significant (*), and those
with a p-value < 0.01 (**), or <0.001 (***), very significant.
Results
Generation of Pichia pastoris-derived clones with VEGF121/
165b overexpression and purification of recombinant
proteins
Figure 1 shows a scheme of the different exons included
in each of the “classical” VEGF-A isoforms and the
“VEGFxxxb” isoforms. The coding sequence for both
VEGF121ba n dV E G F 165b, lacking the native human sig-
nal peptide, was cloned into the pPICZalphaC plasmid.
The native human signal peptide sequence was substi-
tuted by the yeast alpha-factor signal peptide in these
constructs, which is known to be very efficient for secre-
tion in Pichia pastoris. To obtain top-quality recombi-
nant proteins, VEGFxxxb was purified from Pichia
pastoris culture supernatants through nickel-affinity
chromatography. Figure 2A shows a chromatographic
image of the procedure. Recombinant VEGF121bw a s
eluted in a gradient of 20% imidazole. Peak 1 corre-
sponds to all unbound substances, which run through
the column. Peak 2 corresponds to proteins eluted with
approximately 12.5% of imidazole (Figure 2A). Similar
results were found for VEGF165b (not shown). Figure 2B
shows Coomasie blue staining of different aliquots taken
during elution of VEGF121ba r o u n dp e a k2 ,w h e r et h e
bands correspond to the expected size of VEGF121b.
These results show that nickel-affinity is an efficient
method to purify VEGFxxxbp r o t e i n sf r o mPichia pas-
toris culture supernatants.
Electrophoresed culture media from Pichia pastoris
clones obtained after electroporation with the linearized
VEGF121bo rV E G F 165b sequence containing pPICZa-
phaC plasmids and selection with zeocin for one week is
shown in Figure 2C. Bands of the expected molecular
masses were detected in supernatants from Pichia pas-
toris clones. The amount of ectopic protein was clearly
visible among the total secreted proteins by this yeast.
The clones overexpressing higher amounts of recombi-
nant VEGFxxxb proteins were chosen for large-scale
production. Importantly, Pichia pastoris-derived recom-
binant proteins were immunoreactive to the currently
available (and previously validated) commercial antibody
(R&D) against VEGFxxxb (Figure 2D).
Exons included in all transcripts Alternatively spliced exons A
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Figure 1 VEGF-A transcripts generated by mRNA alternative
splicing. Exon organization of VEGF-A gene (A). Exons 1 to 5 are
included in all isoforms (A-C). The 3’ alternative exons 8 and 8b, of
the same length in base pairs, are differentially included in the
“classical” family of VEGF-A isoforms (B) or the novel family of “b
isoforms” (VEGFxxxb) (C).
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Figure 2 Purification of recombinant VEGFxxxbp r o d u c e di n
Pichia pastoris. HPLC elution profile showing the absorbance
overtime, after production of VEGF121b (A). Two peaks are observed
for both isoforms: Peak 1 corresponds to proteins in the P. pastoris
culture supernatants unbound to the column, whereas peak 2
corresponds to the eluted VEGF121b protein. Fractions indicated in
the graphs were electrophoresed and stained with Coomassie blue.
Bands of the expected size were observed in the fractions
corresponding to peak 2 (B). Culture supernatants subjected to
electrophoresis for both VEGF165b and VEGF121b. Under non-
reducing conditions the 3-band pattern (light arrows) corresponds
to dimers (most likely glycosylated-glycosylated, glycosylated-non-
glycosylated and non-glycosylated-non-glycosylated proteins, as
previously described for the VEGF-A classic isoforms). Under
reducing conditions, bands (2-band pattern, as described for VEGF-A
under these conditions) correspond to monomers (C). VEGF121/165b
proteins purified after production in the yeast P. pastoris are
strongly immunoreactive with an antibody raised against
VEGFxxxb. The lanes in the blots show bands of 3 clones with
different amounts of secreted VEGF121b, or 2 clones in the case of
VEGF165b (D).
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pastoris form dimers
The band pattern of recombinant human VEGF121/165b
isoforms expressed in Pichia pastoris was similar to that of
the native VEGFxxx isoforms, as previously described [20].
VEGF121b forms dimers that can be detected in the gel as
three bands under non-reducing conditions (Figure 2C).
The three bands probably correspond to dimers of glyco-
sylated-glycosylated, glycosylated-non-glycosylated and
non-glycosylated-non-glycosylated proteins, as described
for the VEGF-A classic isoforms [20]. The same culture
supernatants run under reducing conditions showed only
two bands (Figure 2C), which would be concordant with
the ability of these proteins to dimerize. The same pattern
can be seen for VEGF165b (Figure 2C), although the bands
are not as clearly seen as for VEGF121b. Recombinant
VEGFxxxb proteins also formed larger complexes, such
as tetramers and octamers, especially in the case of
VEGF165b (Figure 2D).
To assess the glycosylation status of the VEGFxxxb
recombinant proteins produced in Picha pastoris,e n d o -
glycosidase F1 was used both in reducing and non-redu-
cing conditions (Additional file 1 Figure S1). VEGF121/
165b deglycosylation produced an electrophoretic shift
for both isoforms. Molecular weights for both glycosy-
lated and deglycosylated proteins are compatible with
those observed for VEGF121 and VEGF165 [20,21].
Recombinant VEGF121/165b proteins induce proliferation
of HUVEC cells
The effect of VEGF121/165b recombinant proteins pro-
duced in our laboratory (VEGF121b(pp) and VEGF165b
(pp)) was first tested on endothelial cell proliferation in
vitro.W ea l s ot e s t e dt h ee f f e c to faV E G F 165b recombi-
nant protein (VEGF165b(hs)) produced in mammalian
CHO cells to discard any possible yeast-glycosylation-
derived effect. A first experiment was conducted with
the MTT assay. Addition of 100 ng/mL commercial
VEGF165 (from R&D) induced HUVEC proliferation by
63% compared to untreated cells (Figure 3A). Co-
administration of VEGF165 and either VEGF121b(pp),
VEGF165b(pp), or VEGF165b(hs) (at the same dose)
caused a similar proliferativei n d u c t i o n( F i g u r e3 A ) .
Exposure of HUVECs to each one of the recombinant
“b-isoforms” alone resulted in ~40% increased prolifera-
tion. Administration of the VEGFR-targeting compound
GW654652 alone or with VEGF165b ( h s )p r o d u c e ds i m i -
lar rates of HUVECs proliferation than untreated con-
trol cells (Figure 3A). This result shows the specificity of
VEGF165b in inducing VEGFR-mediated endothelial pro-
liferation. Similar results using the VEGFR inhibitor
were obtained for VEGF121b(pp) and VEGF165b(pp)
(results not shown).
To confirm our results on proliferation we used an
alternative method, based on DNA incorporation into
the cells. As shown in Figure 3B, administration of bFGF
and VEGF165 increased DNA incorporation into
HUVECs by 3-fold (p < 0.001), compared to untreated
c o n t r o l s .E x p o s u r et oV E G F 165b(pp) and VEGF121b(pp)
also increased significantly (p < 0.01) DNA incorporation
into HUVECs by almost 2-fold as compared to controls.
Therefore, these experiments parallel those obtained by
MTT showing that VEGFxxxb isoforms increase prolifera-
tion, although less potently than VEGF165.
VEGF121/165b induces phosphorylation of Flk-1/KDR and
its downstream effector p42-44/ERK
Addition of all VEGF-A proteins to HUVECs induced
phosphorylation of the VEGF-A receptor Flk-1/KDR
(also known as VEGFR2) and the intracellular kinase
ERK1/2 (Figure 4). As expected, VEGF165 caused phos-
phorylation of KDR and ERK1/2, 10 min after treatment
in serum-free conditions (Figure 4). VEGF121/165bp r o -
teins induced KDR phosphorylation in HUVECs as well.
VEGF121b and VEGF165b, either produced in mammalian
cells or in Pichia pastoris stimulated similarly ERK1/2
phosphorylation. Co-administration of VEGF165 and
VEGF121/165b did not prevent VEGF165-induced KDR or
ERK1/2 phosphorylation. VEGF165b(pp) failed to activate
the KDR-ERK pathway in the presence of the VEGFRs
inhibitor GW654652, thus indicating receptor specificity.
Similar results were obtained with VEGF121b(pp)
and VEGF165b (hs) (not shown).
VEGF121/165b isoforms stimulate angiogenesis in vivo
Matrigel plug assays were done in order to decipher the
effect of VEGF121/165b isoforms on endothelial cell func-
tion in vivo. Matrigel was mixed with either bFGF, or
VEGF165 (from R&D), or VEGF121b(pp), or VEGF165b(pp).
Blood vessels within the Matrigel plugs were identified by
the presence of Alexa-647-labelled isolectin B4 (Figure
5A), which was injected systemically into the mice before
the sacrifize. No signal from the Alexa-647-labelled lectin
was observed in control Matrigels, whereas plugs carrying
any of the VEGFxxxb isoforms showed a strong signal, thus
demonstrating angiogenesis in vivo (Figure 5A). To ana-
lyze vascular permeability, FITC-labelled-dextran was
injected in another set of mice with Matrigel plugs under
similar experimental conditions (Figure 5B). Whereas
almost no fluorescent signal was seen in control plugs, in
Matrigels that were pre-loaded with bFGF or especially
with VEGF121b, a dramatic increase in the fluorescent sig-
nal was found. Matrigel plugs carrying either VEGF165 or
VEGF165b displayed a similar degree of fluorescence,
which was approximately 10-fold higher than that of
controls.
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and angiogenesis in vivo
A cell line with high (PC-3) and another one with low
(A549) endogenous total VEGF expression levels were
selected for in vivo assays (Figure 6A). VEGF121/165b
isoforms were overexpressed in both PC-3 and A549
xenograft models in order to assess the effect of these
isoforms in tumor growth and angiogenesis. Western
blot analyses showed a high expression of either
VEGF121bo rV E G F 165b in cell pools that were selected
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Page 7 of 14with G418 over a period of 20 days (Figure 6A). No sta-
tistical differences in tumor growth were seen between
controls and tumors overexpressing either VEGF121b, or
VEGF165b, or a combination of both in PC3 xenografts
(Figure 6B). Moreover, VEGF121b-overexpressing cells
tended to form bigger tumors than the rest of the
experimental conditions (Figure 6B). In the case of
A549 xenografts, significant increases in tumor volumes
were found when cells with either VEGF121b, or
VEGF165b were injected, in comparison with controls
(Figure 6C). Therefore, overexpression of the VEGF121/
165b isoforms does not cause tumor shrinkage but
tumor growth in these models.
Analysis of angiogenesis revealed that A549 tumors were
less angiogenic than PC-3 tumors with no differences
between controls and the experimental groups (Figure 7).
In PC-3, VEGF121b-overexpressing tumors showed a sig-
nificantly higher (p < 0.05) vascularization than the other
experimental groups (Parental, Mock-transfected and
VEGF165b). To analyze a possible mural recruitment to
the vasculature, levels of PDGFRb were analyzed by
immunhostochemistry and image analysis. PDGFRs are
expressed in pericytes and bone-marrow-derived cells that
participate in blood vessel formation and coverage (22).
Therefore, if VEGFxxxb isoforms alter the vascular wall, a
decrease in PDGFRb+ cells should be found in compari-
son with controls. However, no such decrease was
observed in either PC-3 or A549 xenografted tumors
(Additional File 2 Figure S2). We also quantified the num-
ber of apoptotic cells in these tumors, since an anti-
p
)
p
)
s
)
p
)
p
)
s
)
E
G
F
1
2
1
b
 
(
p
p
E
G
F
1
6
5
b
 
(
p
p
E
G
F
1
6
5
b
 
(
h
s
P
M
 
G
W
o
n
t
r
o
l
E
G
F
1
6
5
E
G
F
1
2
1
b
 
(
p
p
E
G
F
1
6
5
b
 
(
p
p
E
G
F
1
6
5
b
 
(
h
s
E
G
F
1
6
5
+
 
V
E
E
G
F
1
6
5
+
 
V
E
E
G
F
1
6
5
+
 
V
E
E
G
F
1
6
5
b
 
+
 
1
C
o
V
E
V
E
V
E
V
E
V
E
V
E
V
E
V
E
pKDR
KDR
pERK1/2
ERK1/2
Figure 4 VEGF121/165b isoforms activate the ERK signalling
pathway through VEGF receptors. Effect of VEGF121/165b isoforms
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Figure 5 VEGF121/165b isoforms induce vascularization in vivo.
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translated into an increase in apoptosis. In A549 xeno-
grafts, no changes were observed in the number of active
caspase-3+ cells (Additional File 2 Figure S2). In PC-3
xenografted tumors, not an increase but a reduction in the
number of apoptotic cells was observed when VEGFxxxb-
overexpressing cells were injected, as compared to con-
trols (Additional File 2 Figure S2). A significant reduction
(~2-fold, p < 0.05) was found for VEGF121b, which is in
keeping with the increased vascularization of these tumors.
Expression of VEGFxxxb proteins and total VEGF-A in a set
of normal breast and breast cancer samples
Previous studies had suggested that VEGFxxxbi s o f o r m s
can be differentially expressed in normal vs. pathological
conditions [13]. To study if this was the case for breast
cancer, we used a TMA containing core biopsies from
breast cancer patients and normal breasts. To this end,
we used a well validated antibody that recognizes total
VEGF-A (including all VEGF-A isoforms) (R&D sys-
tems) and the only available and validated anti-
VEGFxxxb antibody that recognizes all the VEGFxxxb
proteins (R&D systems) [18]. No available antibody spe-
cific for the “non-b” isoforms (VEGFxxx) is currently
available.
Figures 8A and 8B show representative images of
malignant and normal breast tissues stained with the
anti-VEGFxxxb and anti-total VEGF-A antibodies. Strong
staining for VEGFxxxb could be seen in tumor cells of
infiltrating ductal carcinoma (IDC) samples. Staining
w a sa l s of o u n df o ro t h e rt y p e so ft u m o r s ,i n c l u d i n g
papillary carcinoma (Pap), phyllodes (Phy), infiltrating
lobular carcinomas (ILC), and ductal carcinoma in situ
(DCIS). No VEGFxxxb was detected in any of the normal
breast tissue (NBT) samples. All tissues analyzed were
positive for total-VEGF-A, including the normal breast
epithelium. Semiquantification of the staining showed
that both total VEGF-A and VEGFxxxb protein levels
were significantly higher (p < 0.05) in IDC than in nor-
mal breast tissues (Figures 8C and 8D). A significant (p
= 0.033) positive correlation index (r = 0.404) between
VEGFxxxb and total-VEGF-A was found, thus indicating
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Page 9 of 14the degree of co-staining. Therefore, we conclude that
VEGFxxxb levels are not reduced in malignant breast
cancer but, on the contrary, tend to increase in the
tumor samples and are significantly higher in infiltrating
ductal carcinomas.
Discussion
The importance of VEGF-A in normal and pathological
angiogenesis has been widely explored and documented
in the last decades [6]. VEGF-A has become a major tar-
get for cancer therapy in solid tumors, and VEGF-
targeted drugs, such as bevacizumab or sunitinib are
currently being used in patients [9,10]. The biology of
VEGF-A spliced isoforms is, however, poorly understood
yet. In particular, understanding how the different
VEGF-A isoforms are generated through alternative spli-
cing may be important to design more specific and
effective molecular therapies.
In 2002, a new family of VEGF-A isoforms generated
by alternative splicing was reported [14,19], which were
denominated VEGFxxxb isoforms. These transcripts
incorporate a different exon (called exon 8b, sequence
SLTRKD) from the classical exon 8a (sequence
CDKPRR) found in the angiogenic transcripts [19].
I n c l u s i o no fe x o n8 bw a st h o u g h tt oe n d o wV E G F xxxb
isoforms with the capacity to bind VEGF-A receptors
without strong downstream signalling activation [14].
Because of this property, the VEGFxxxbp r o t e i n sw e r e
hypothesized to be antiangiogenic [14]. Although results
have to be interpreted carefully, it was shown that over-
expression of VEGF165bo rV E G F 121bi nt u m o rc e l l s
xenotransplanted into nude mice results in growth inhi-
bition [14,18,23-25]. Another interesting finding that
was reported is that VEGFxxxb isoforms may be differen-
tially expressed in pathological tissues compared to nor-
mal tissues [13,25,26]. Changes in the natural splicing
w o u l df a v o rt h ea m o u n to ft h eV E G F xxx transcripts in
some aberrant angiogenesis-linked diseases, at the
expense of reducing the amount of the VEGFxxxbi s o -
forms (mainly expressed in normal tissues).
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f i n d i n g s ,w ea i m e di nt h ep r e s e n ts t u d yt op r o d u c e
VEGF121ba n dV E G F 165b recombinant proteins in the
yeast Pichia pastoris, with the goal of testing their anti-
angiogenic/antitumor properties in vitro and in vivo.
Generation of VEGF121/165b-overexpressing cancer cells
using the PCDNA3.1 plasmid was also used for this pur-
pose. The yeast expression system was chosen for sev-
eral reasons. First, this system allows protein
glycosylation, and purification with little secretion of
yeasts-derived endogenous proteins that may contami-
nate the recombinant protein of interest. Another
advantage is that protein production is easier, faster and
cheaper than that generated in mammalian systems. In
addition, we made sure with this expression system that
no exon 8-containing VEGF-A contamination is present,
since yeasts do not code for any form of VEGF. Produ-
cing VEGF-A in mammalian cells has the drawback of
possible formation of exons 8 and 8b heterodimers. This
may be of special importance, since VEGF-A is secreted
and active in its dimeric form [6].
We have successfully produced recombinant
VEGF121ba n dV E G F 165b proteins that share similar
structural characteristics to those of the classical
VEGF121 and VEGF165 proteins: Ability to form dimers
or multimers, and reactivity with commercial antibodies
that were raised against exons 1 to 5 (common to all
VEGF-A isoforms). In addition, both recombinant
VEGF121ba n dV E G F 165b proteins were immunoreactive
with a validated antibody that recognizes exon 8b (from
R&D [18]).
To test the functionality of these isoforms in vitro,
HUVECs were treated with recombinant proteins pro-
duced in yeasts, VEGF165b produced in mammalian
cells, or the “classical” VEGF165 angiogenic protein (as
control). All treatments were carried out in serum-free
media. We found that VEGF121/165b isoforms induced
proliferation of HUVECs and phosphorylation of
VEGFR2 and its downstream transducer ERK. The effect
of VEGF121/165b isoforms was milder than that found for
VEGF165: Proliferation of HUVECs was ~50% less sti-
mulated with VEGF121/165b isoforms than that using
recombinant VEGF165. However, the degree of ERK acti-
vation was similar for all the proteins tested, 10 min
after stimulation. This intracellular effector was phos-
phorylated specifically by VEGFRs, as demonstrated by
the inhibition of such process in the presence of the
VEGFR1 and VEGFR2 tyrosine-kinase inhibitor
GW654652.
Kawamura et al. [16] have demonstrated that VEGF165b
displays unique functional characteristics. They showed
VEGF165b to be a weak agonist of VEGFR2 and to induce
its phosphorylation in HUVECs with a similar potency as
VEGF145. Similarly to VEGF121,V E G F 165b does not bind
neuropilin-1 (NRP1) and failed to induce complexes
between NRP1 and VEGFR2. VEGF165b promotes cell
migration (in PAE cells transfected with VEGFR2), simi-
lar to VEGF165,V E G F 145,a n dV E G F 121 isoforms. Resem-
bling the activity of VEGF121 and VEGF145, but unlike
VEGF165,V E G F 165b does not induce endothelial sprout.
But unlike the other isoforms, VEGF165b was unable to
phosphorylate the mouse VEGFR2 at the Y1052 position.
Unfortunately, downstream signalling activation was not
tested in this study [16]. Authors hypothesized that
VEGF165b is not able to fully rotate the receptor’si n t r a -
cellular tail upon binding, thus blocking to some extent
transphosphorylation [16]. In addition, Glass et al. [17]
have shown that VEGF165b activates transiently VEGFR1
in order to elicit vascular permeability in the mesenteric
vein. Collectively, these and our results suggest that
VEGF165b may exert weak downstream signalling in
endothelial cells. However, depending on the cellular
context (for instance, the presence of NRP1 or the
amount of VEGFR1 or VEGFR2), VEGF165bm a yb l o c k
transphosphorylation to p r o d u c ean o n - a n g i o g e n i c
response.
To further validate the observation of VEGF121/165b
angiogenic properties seen in classical in vitro assays, we
conducted in vivo experiments with Growth Factor
Reduced Matrigel, in which VEGF, among other angio-
genic cytokines, have been significantly depleted. Addi-
tion of recombinant VEGF121b, or VEGF165b, or
VEGF165 caused recruitment of blood vessels to the
Matrigel compared to PBS-loaded controls, thus demon-
strating an angiogenic effect. It is worth mentioning that
VEGF121b-containing Matrigels we r eh i g h l ye n r i c h e di n
dextran-FITC signal, which seemed to be within and out
of the vessels (similar to results found for bFGF). This
suggests an increase in vascular permeability, in keeping
with vascular permeability described for VEGF121 [27].
The ability to inhibit tumor growth in vivo was tested
in our study by VEGF121/165b overexpression in xeno-
graft models. We chose two different cancer cell lines:
The low-VEGF-expressing lung adenocarcinoma A549
cell line (~1-5 pg/mL (28)) and PC-3, a prostate cancer
cell line that secretes ~800 pg/mL; [29]. These cell types
were chosen to ascertain possible differences in the
VEGFxxxb behavior depending on the endogenous VEGF
expression. Experiments were performed without any
further exogenous VEGF stimulation, such as transfec-
tion of VEGF. In the PC3 xenografts, no statistical dif-
ferences between controls and VEGF121/165b-expressing
tumors were seen. However, a tendency of VEGF121b-
overexpressing tumors to grow at a faster rate than the
other groups was found. In agreement with these
results, vascular density for VEGF121b-overexpressing
PC-3 tumors was significantly higher than that observed
for the rest of the groups, and apoptotic levels
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formed small tumors after subcutaneous implantation in
nude mice, as previously described [30]. Strikingly, over-
expression of VEGF121/165b in these cells resulted in a
significant increase in tumor development over the con-
trols, although no differences in vascular density were
found between groups, which may be due to the poor
angiogenic potential of these tumors.
These results are in conflict with previous reports
showing that VEGF165b causes anti-tumor effects
[14,15,23,24]. Our interpretation for these seemingly
contradictory results is as follows: The in vivo models in
which the VEGFxxxb isoforms have been proven to be
efficacious in reducing tumor growth expressed high
VEGF levels (either by the nature of the cells used or by
transfection with VEGF-carrying plasmids). In these
conditions, both VEGFxxx and VEGFxxxb proteins would
compete equally for receptor binding. Because VEGFxxxb
is only able to signal weakly, a reduced tumor volume
will be observed when tumors overexpressing VEGFxxxb
are compared to high VEGF-expressing tumors. How-
ever, in the case of tumors with low VEGF production,
overexpression of VEGFxxxb would stimulate tumor
growth to a certain extent. Thus, in CAKI cells, where
endogenous total VEGF levels are ~900 pg/mL [23],
when both parental and VEGF165b-overexpressing cells
were injected into mice, no differences in tumor growth
were found. Only when parental cells were transfected
with VEGF165,ar e d u c t i o ni nt u m o rv o l u m ew a s
observed compared to VEGF165b-overexpressing tumors
[23]. Similarly, significant differences in tumor volumes
were only obtained in Mel57 (<600 pg/mL, [31]) and
A375 (~600 pg/mL, [32]) melanoma xenograft models
when VEGF165-a n dV E G F 165b-overexpressing clones
were compared [14,23]. On the contrary, in LS174t cells,
which secrete high VEGF levels (~2000 pg/mL, [33]),
overexpression of VEGF165bo rV E G F 121b[ 1 5 ] ,o r
administration of VEGF165b recombinant protein [24]
led to tumor shrinkage compared to controls (parental
cells with no further VEGF overexpression). CT71
Ewing sarcoma cell lines produce ~1200 pg/mL, [34].
When CT71 cells overexpressing VEGF165b were xeno-
transplanted into nude mice, a significant reduction in
tumor volume was found when compared with untrans-
fected CT71 xenografts [23].
It is possible then that therapies based on the adminis-
tration of VEGFxxxb proteins are effective in tumors
with high endogenous VEGF expression. However, the
use of this therapy in tumors with low VEGF levels,
which likely rely on other angiogenic factors for their
growth (such as bFGF, IL-8, etc.) may worsen the evolu-
tion of the tumor. Therefore, therapy with VEGFxxxb
casts some doubts about its possible use in unselected
patients. Caution must be taken in defining which
possible patient will benefit from VEGFxxxb-based thera-
pies. Stratifying the patients based on the amount of
VEGF production may be critical for future possible
clinical trials.
But before translating this type of therapy, many
aspects of the VEGFxxxb biology should be clarified. For
instance, it is quite surprising that VEGF121b, although
found to inhibit endothelial cell migration, was cytopro-
tective for endothelial cells (in serum starvation experi-
ments), in a similar way as VEGF165 [15]. Such
cytoprotection involved activation of VEGF receptors
and downstream signalling [15]. Even more surprising is
the fact that in some xenograft models (for instance
using CAKI cells), co-overexpression of VEGF165 and
VEGF165b results in tumors that are smaller in size than
those generated by overexpression of just VEGF165b
[23]. Other issues, such as whether or not VEGFxxxb
proteins are able to heterodimerize with members of the
VEGFxxx angiogenic family, should be clarified as well.
We have also addressed in this study the issue of
whether the VEGFxxxb isoforms may be differentially
expressed in malignant tissues (human breast cancer)
compared to healthy tissues (normal mammary gland).
For our experiments we used immunohistochemistry
with validated antibodies specific for all VEGFxxxbi s o -
forms and antibodies that recognize all VEGF tran-
scripts. Our results revealed that both total VEGF and
VEGFxxxb levels tended to increase in breast cancer
samples (n = 50) compared to normal breast tissues
(n = 8). This increase was statistically significant for
intraductal carcinomas (IDC). Expression of both total
VEGF and VEGFxxxb were significantly correlated, thus
suggesting that both families of VEGF (VEGFxxx and
VEGFxxxb) follow a similar pattern of expression.
Previous studies have analyzed, in a limited number of
samples, expression of the VEGFxxxb isoforms. Whereas
total VEGF mRNA levels were found significantly up-
regulated in colon carcinoma samples (n = 6) compared
to controls, no changes were observed for VEGFxxxb
mRNA levels [18]. This result shows that the increase in
total VEGF is due to the VEGFxxx angiogenic isoforms
[18]. A similar result was found analyzing protein levels
by isoform-specific ELISAs [18]. RT-PCR analysis
showed that VEGF165b was present in 17 of 18 normal
kidney samples, but only in 4 of 18 matched malignant
tissues [19]. Immunohistochemical analysis of 19 mela-
noma samples (9 metastatic and 10 nonmetastatic)
using the VEGFxxxb specific antibody, found a decrease
in VEGFxxxb expression in the neoplastic tissue (espe-
cially in metastasis) compared to the normal skin [25].
The lack of appropriate antibodies specific for each of
the VEGFxxx and VEGFxxxb proteins hinders the fine
characterization of the pattern of expression in malig-
nant and normal tissues. Future studies using larger
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and immunohistochemical analyses would be needed to
assess whether VEGFxxxb expression could be used as a
cancer biomarker.
Conclusions
Our results demonstrate that VEGF121/165b are not anti-
angiogenic, but weakly angiogenic isoforms of VEGF-A
that may foster tumor growth and angiogenesis in vivo.
We also conclude that VEGFxxxb isoforms (as well as
total VEGF levels) are up-regulated in breast cancer in
comparison with non malignant breast tissues.
Additional material
Additional file 1: Figure S1. Deglycosylation of VEGF121b and
VEGF165b proteins produced in Pichia pastoris in reducing and non-
reducing conditions. Treatment of both proteins with Endoglycosidase
F1 produces an electrophoretic shift. VEGF121b and VEGF165b are
glycosylated and the molecular weights of both glycosylated and
deglycosylated proteins are compatible with those described for VEGF121
and VEGF165. In non-reducing conditions, glycosylated dimers of
VEGF121b and VEGF165b display 41 and 28 KDa molecular weight,
respectively, as previously described. After deglycosylation, molecular
weight of dimers is decreased by around 10 KDa, similar to mammalian
deglycosylation of VEGF. Under reducing conditions (where monomers
are observed) both VEGF121b and VEGF165b glycosylated bands disappear
upon Endoglycosidase treatment. The 30 KDa band that is observed in
reducing conditions corresponds to the Endoglycosidase F1 present in
the mixture reaction.
Additional file 2: Figure S2. Analysis of active caspase-3 and
PDGFRb protein expression in sections from xenografted tumors.
Immunostaining for active caspase-3 in A549 tumors shows no changes
in apoptotic rates in VEGF121/165b-overexpressing tumors, as compared
with controls. In PC-3 tumors, a significant reduction in apoptosis is
observed for VEGF121b when compared to controls.
Immunohistochemistry for PDGFRb+ cells shows no differences in
expression between controls and VEGF121/165b-overexpressing groups, in
either PC-3 or A549 xenografted tumors.
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